Retatrutide
Retatrutide (LY-3437943, Triple Agonist)
Last updated: March 2026
Key Benefits
How It Works
Retatrutide is a first-in-class triple hormone receptor agonist that activates GIP, GLP-1, and glucagon receptors simultaneously. The addition of glucagon receptor activation enhances energy expenditure and fat oxidation beyond what dual agonists achieve. Phase 2 trials showed unprecedented weight loss of up to 24% body weight.
Research Highlights
Available Forms
- Subcutaneous injection
- Lyophilized powder (research)
Research Dosing
Phase 2 protocols used doses ranging from 0.5mg to 12mg weekly subcutaneous. Optimal dose appears to be 8-12mg/week based on efficacy/tolerability balance.
⚠️ For research reference only. Not medical advice.
Legal Status
Retatrutide is an investigational drug in Phase 3 clinical trials by Eli Lilly. Not yet approved in any country. Research-grade available from peptide suppliers.
Check legal status by country →